According to the authors of a study from Paris, France, "CK2 represents an oncology target scientifically validated. However, clinical research with inhibitors of the CK2-mediated phosphorylation event is still insufficient to recognize it as a clinically validated target."
"CIGB-300, an investigational peptide-based drug that targets the phosphoaceptor site, binds to a CK2 substrate array in vitro but mainly to B23/nucleophosmin in vivo. The CIGB-300 proapoptotic effect is preceded by its nucleolar localization, inhibition of the CK2-mediated phosphorylation on B23/nucleophosmin and nucleolar disassembly. Importantly, CIGB-300 shifted a protein array linked to apoptosis, ribosome biogenesis, cell proliferation, glycolisis, and cell motility in proteomic studies which helped to understand its mechanism of action. In the clinical ground, CIGB-300 has proved to be safe and well tolerated in a First-in-Human trial in women with cervical malignancies who also experienced signs of clinical benefit. In a second Phase 1 clinical trial in women with cervical cancer stage IB2/II, the MTD and DLT have been also identified in the clinical setting. Interestingly, in cervical tumors the B23/nucleophosmin protein levels were significantly reduced after CIGB-300 treatment at the nucleus compartment. In addition, expanded use of CIGB-300 in case studies has evidenced antitumor activity when administered as compassional option," wrote S.E. Perea and colleagues (see also Synthetic Peptides).
The researchers concluded: "Collectively, our data outline important clues on translational and clinical research from this novel peptide-based drug reinforcing its perspectives to treat cancer and paving the way to validate CK2 as a promising target in oncology."
Perea and colleagues published the results of their research in Molecular and Cellular Biochemistry (CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Molecular and Cellular Biochemistry, 2011;356(1-2):45-50).
For additional information, contact S.E. Perea, Chemo Group, Paris, France.
The publisher of the journal Molecular and Cellular Biochemistry can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.
Keywords: City:Paris, Country:France, Region:Europe, Biotechnology, Chemicals
This article was prepared by Clinical Trials Week editors from staff and other reports. Copyright 2011, Clinical Trials Week via NewsRx.com.
http://go.galegroup.com/ps/i.do?id=GALE%7CA272930596&v=2.1&u=mode19592&it=r&p=ITOF&sw=w
Gale Document Number: GALE|A272930596
-----Original Message-----
From: guyperea@gmail.com
Sent: 11/28/2011 8:11:19 PM
To: guyperea@live.com
Subject: General OneFile:Research on Synthetic Peptides Reported by S.E. Perea et al
| The United States Department of Health under Secretary Karen O'lari shall review finding from France. |
| General OneFile |
| "Research on Synthetic Peptides Reported by S.E. Perea et al." Clinical Trials Week 21 Nov. 2011: 97. General OneFile. Web. 28 Nov. 2011. Document URL http://go.galegroup.com/ps/i.do?id=GALE%7CA272930596&v=2.1&u=mode19592&it=r&p=ITOF&sw=w |
| Copyright and Terms of Use: |
| http://www.gale.com/epcopyright |
very interesting post.this is my first time visit here.i found so many interesting stuff in your blog especially its discussion..thanks for the post! usa peptides
ReplyDelete